The purpose of this review is to describe recent clinical trial, laboratory and observational findings that highlight both the progress that can be achieved in elimination of new pediatric infections in international clinical trial settings among HIV-infected breastfeeding women while also describing recent safety concerns related to currently used antiretroviral regimens. The article will also address the ongoing adherence challenges for HIV-infected mothers in taking their antiretroviral drugs. This information is timely and relevant as new regimens are being considered for both prevention of mother-to-child transmission (PMTCT) of HIV and HIV treatment options worldwide.
INTRODUCTION
This review will focus on recent research findings on prevention of mother-to-child transmission of HIV (PMTCT) in resource-limited international settings, including the efficacy and safety findings from the recently completed multisite PROMISE 1077 trial. This update also highlights the steady progress in prevention of perinatal HIV transmission prevention worldwide since the dramatic results of the first successful perinatal prevention trial ACTG 076 using zidovudine (ZDV) were announced in 1994 [1] . Since that time, major advances in PMTCT have continued worldwide with transmission rates dropping from one in three newborns of HIV-infected women becoming infected to less than one in a hundred with available combination antiretroviral therapy (ART) in the recent PROMISE 1077 randomized trial (Table 1) . However, ART regimens have also been documented to be associated with certain safety concerns for both mothers and their infants. Thus, the quest continues for the optimal antiretroviral regimen for mothers and their infants in terms of both safety and effectiveness.
Snapshot of the global perinatal HIV epidemic
In 2016, UNAIDS reported that 160,000 infants worldwide had acquired HIV infection from mother-to-child-transmission of the virus; with greater than 90% of the new pediatric HIV infections occurring in Africa [2 Substantial progress has been made in the worldwide reduction of HIV transmission from mothers to their children over the past decade with most recent reductions related to the roll out of 'Test and Treat.' However, current ART strategies are associated with increased risk of adverse pregnancy outcomes including low birthweight and PTD with the use of maternal ART compared to ZDV regimens as highlighted with the PROMISE 1077BF/1077FF clinical trial data.
Maternal adherence to taking lifetime HIV treatment remains a major challenge: increasingly high rates of maternal HIV resistance to NNRTIs and NRTIs are being documented among newly diagnosed HIVinfected pregnant women; as well as among HIVinfected young children being started on antiretroviral treatment. the late 1990s in the United States and Europe, with the use of dual and then triple antiretrovirals during pregnancy followed by 6 weeks of ZDV prophylaxis to newborns, along with the avoidance of breastfeeding, perinatal transmission rates had declined to less than 3% among women who were tested and begun on antiretrovirals during pregnancy [7, 8] .
Internationally, in resource-constrained settings such as Africa and midlevel settings in the Far East, the initial focus was on testing cost-effective and deliverable shorter course prevention of transmission in the peripartum period, including the third trimester and at labor/delivery where two thirds of perinatal HIV infections were estimated to occur [9] . These trials included short course ZDV trials, single-dose SD oral nevirapine (SD-NVP) given to the mother at labor onset and to her newborn. Transmission rates in Thailand with short course ZDV were reduced by 50% compared to no intervention [10] and also with the use of single-dose peripartum NVP in Uganda compared to 1-week peripartum ZDV [11] . However, later, HIV transmission continued to occur during extended lactation [12, 13] and accounted for up to one-third of all HIV transmission to infants in breastfeeding settings [9] . Initial approaches by WHO [14] were then to recommend shortened periods of breastfeeding for HIV-infected women but this then led to increased mortality because of competing causes of infant mortality such as diarrhea and malnutrition that extended breast feeding protected against. In 2010 and 2016, WHO revised its guidance on infant feeding to recommend extended breastfeeding for HIV infected women but with the use of ARVs to reduce the risk of HIV transmission [15, 16] . Given the need for extended breastfeeding for overall early child survival particularly in resource-limited settings in Africa where safe water and affordable breastmilk substitutes are not widely available, more recent perinatal HIV trials then focused on protecting the infant from HIV infection throughout extended breastfeeding by the use of ARVs given either to the breastfeeding mother or to her HIV-exposed infant [17, 18] 
PROMISE trial and other recent research prevention of mother-to-child transmission results
In order to address remaining research gaps in PMTCT, the multiversion, multisite randomized open label PROMISE 1077 trial was conducted between 2011 and 2016 to address the optimal antiretroviral regimens for PMTCT and maternal treatment balancing the relative safety and efficacy of already proven antiretroviral regimens for PMTCT among asymptomatic HIV infected women who did not meet country criteria for HIV treatment at the time of the trial. The 1077BF and 1077FF versions of the PROMISE protocol were designed for resourcelimited international settings where the use of antenatal ZDV followed by SD-NVP was recommended as standard of care for PMTCT; and where either extended breastfeeding was recommended; or for those HIV-infected women who could safely formula feed in settings where formula was available and water supply was safe. In the 1077BF PROMISE protocol (Fig. 3 schema [19] ), HIV-infected pregnant women were randomized in the antepartum period to either ZDV and SD-NVP with a 'tail' of tenofovir/ emcitrabine (TDF/FTC) or to maternal ART using either TDF/FTC with lopinavir/ritonavir (Lop/r) or ZDV/3TC with Lop/r; in the postpartum breastfeeding period to either maternal ART with TDF/FTC/ Lop/r or infant daily NVP; and in the maternal health component at breastfeeding cessation, to either continue or stop maternal ART [29 && ].
Antepartum PROMISE results
The multisite PROMISE 1077BF/1077FF antepartum results were published in November 2016 based on randomized trial data from six countries in Southern and East Africa, and from India, among 3490 HIVinfected pregnant women with CD4 cell counts at least 350 cells/mm 3 who did not meet country criteria for treatment [29 && ]. Maternal median age was 26 years at entry, median gestational age was 26 weeks and median CD4 cell count was 530 cells/ mm 3 . The antepartum PROMISE results were that both the ZDV antepartum regimen with single-dose NVP and 2-week 'tail' of TDF/FTC and the maternal ART regimens with either ZDV/3TC/Lop/r or TDF/ FTC/Lop/r achieved transmission rates below 2%; the maternal ART regimen transmission rates were significantly lower compared to the ZDV regimen at 0.56 versus 1.8%, and repeated confidence interval (CI) difference was À1.3 (À2.1 to À0.4). However, the PROMISE results also found a significantly increased risk of preterm delivery (PTD), 20.5 versus 13.1%, P < 001 or low birth weight (LBW 12 versus 23%, P < .001) or composite adverse outcome (40 versus 27.5%, P < .001) for women randomized to the maternal ART regimens compared to the antenatal ZDV regimen; as well as increased rates of maternal liver function toxicity for the maternal ART arms. The overall conclusions from the PROM-ISE antepartum results were to support not only the WHO recommendations for the use of maternal ART for PMTCT, but also the importance of follow up of infant survival and testing of new ART regimens to see if they might ameliorate the increased risk of adverse pregnancy outcomes found with maternal ART regimens compared to ZDV.
Post partum PROMISE results
The postpartum results of the PROMISE 1077BF addressing the relative safety and efficacy of regimens to reduce the risk of transmission of HIV during breastfeeding were presented in July 2016 [30] . This part of the PROMISE trial randomized postpartum women at the 1-week post delivery visit (6-14 days postpartum) to receive either maternal FIGURE 3. PROMISE Trial 1077BF Schema: In the antepartum component, pregnant HIV-infected women were randomized to one of three regimens: either maternal zidovudine (ZDV) or one of two maternal antepartum triple antiretroviral regimens: antepartum zidovudine/lamivudine/ lopinavir/ritonavir or tenofovir/emtracitibine/lopinaovir/ ritonavir. In the postpartum component, HIV-infected mothers or their newborns were randomized to either receive daily maternal triple antiretroviral prophylaxis, tenofovir/ emcitrabine/lopinaovir/ritonavir; or to daily infant nevirapine, using WHO weight-adjusted dosing through 18 months post delivery or cessation of breastfeeding, whichever occurred sooner. In the maternal health component, HIV-infected mothers who had been randomized to postpartum triple ARVs were randomized at entry into maternal health component to either continue or stop triple antiretrovirals at 18 months post delivery; or at the cessation of breastfeeding, whichever occurred sooner. The mothers were then followed to the end of PROMISE. Based on [19] . ART, antiretroviral therapy.
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ART (TDF/FTC/Lop/r) or for their infant to receive daily infant NVP. There were 2431 postpartum women randomized including 1220 women to the maternal ART arm and 1211 women to the infant NVP arm. The mothers' median age was 26 years and median CD4 cell count was 686 (533-869) cells/ mm 3 with no significant differences found in study arm; average duration of breastfeeding was 16 months. Findings were that overall transmission through the duration of breastfeeding as measured at 18 months post delivery was extremely low with either of the two regimens: 0.57 and 0.58% for the maternal ART and infant NVP arms, respectively. Both maternal ART and infant NVP prophylaxis throughout breastfeeding were safe and with no significant differences in maternal progression to AIDS or death events.
Maternal Health PROMISE results
The Maternal Health PROMISE results of 1077BF/ 1077FF were also presented in July 2016 and found no significant differences in disease progression to AIDS or death for mothers randomized to stop versus continue maternal ART after the period of risk of transmission of HIV to the infant was over [31] . The median maternal age was 26 years, 97% were WHO clinical stage 1, median CD4 cell count was 698 cells/mm 3 and the majority of women were Black African (97%). After a median follow-up of 1.6 years, the primary composite endpoint rate of AIDS or death was 0.49 person years and not significantly different between arms. However, WHO stage 2 and 3 events were reduced with continued ART [Hazard Ratio (HR) 0.60; 95% CI 0.39, 0.90, P ¼ 0.01]. The PROMISE results on lack of progression to AIDS or death contrast with the START trial results [32] conducted in general adult populationswhich may reflect the younger age of the women in PROMISE and their generally asymptomatic status with high CD4 cell counts.
PROMISE substudy findings on maternal bone/kidney health
Currently, TDF-based ART is the preferred regimen for HIV-infected pregnant women according to both US and WHO guidelines [4,5 & ]. However, there are concerns that TDF exposure may be associated with maternal bone or kidney health adverse effects. In a PROMISE substudy (P1084 s), there were no concerns regarding kidney toxicity with no differences in creatinine clearance by study arm for TDF versus other regimens. However, P1084s did demonstrate a significantly greater decline in bone mineral density (BMD) from weeks 1 to 74 postpartum among HIV-1 infected breastfeeding mothers randomized to receive TDF-based ART versus mothers not randomized to ART (i.e. whose infants received NVP for the duration of breastfeeding); with a mean maternal hip BMD change of À2.29% (À3.20 and À1.39%), P value less than 0.001; and mean lumbar spine BMD change of À2.86% (À4.03 and À1.70) for mothers on ART compared to mothers whose infants were on NVP, P value less than 0.001 [33 & ]. Future research is planned to explore alternatives to TDF use during pregnancy and breastfeeding periods. Tenofovir alafenamide fumarate (TADF)-based ART has similar efficacy but more favorable safety profile than TDF-based ART [34] . IMPAACT 2010 a phase III, randomized, open-label study among HIV-1 infected pregnant women will assess the relative safety and efficacy of Dolutegravir and TADF/FTC-based ART compared to efavirenz (EFV)/TDF/FTC-based ART [35] . In addition, an ongoing PEPFAR-funded observational follow up of mothers in the PROMISE trial will assess if lifetime ART is associated with further BMD decreases with repeat pregnancy and breastfeeding. See Table 1 summary 1077BF results.
Other recent trial and safety findings
Apart from the PROMISE randomized clinical trial results [29 && ], other recent trials explored different ART regimens and infant prophylaxis for prevention of perinatal HIV transmission. In a recent Thailand study, increased perinatal transmission risk associated with less than 8 weeks of maternal ART prophylaxis was reported in the Perinatal HIV Prevention Trial PHPT-5 trial [36] . In the ANRS 12174 trial, infants randomized to daily LPV/r versus daily 3TC had similar rates of postnatal transmission and HIV-free survival rates at 50 weeks of age, respectively [37] . And in a recent Ugandan study, there were no significant differences in HIV-free survival among children born to HIV-infected mothers randomized to AZT/3TC/LPV/r versus AZT/3TC/EFV, initiated at 12-28 weeks' gestation and continued through labor, and the duration of breastfeeding through 1 year [38] .
Increasing rates of resistant mutations in perinatal populations
As described in a 2017 meta-analyses review, Boerma et al. [39 & ] documented increasingly high rates of ARV resistance over the past decade among HIVinfected infants and young children (47%) in 13 countries who failed PMTCT; as well as resistant virus among HIV-infected children not reported to be exposed to PMTCT antiretrovirals (26.8%). These include studies from Southern and East Africa [40] [41] [42] as well as West Africa with the highest proportion of resistance being to nonnucleoside reverse transcriptase inhibitors (NNRTIs) followed by nucleoside reverse transcriptase inhibitors (NRTIs) [43, 44] . Likewise, HIV-infected pregnant women in international settings have also shown increased rates of resistance to NNRTI and NRTIs with a study from KwaZulu-Natal, South Africa [45] , reporting 65% of pregnant women having an NNRTI resistance and 7% with Thymidine Analog Mutation resistance using ultra-deep sequencing (UDS) assays; and a study from Tanzania reported similar findings with drug-resistance mutants in 69% of women based on UDS assays [46] . Persistence of resistant mutations at low levels has been documented in adult European studies to be associated with increased risk of treatment failure [47] . The high rates of persistent NNRTI mutants suggest that Protease Inhiibitor or integrase inhibitor regimens may need to be continued for infected children over 3 years of age to ensure long-term treatment success.
CHALLENGES AND RESEARCH GAPS
Despite these remarkable advances in prevention strategies, there are multiple remaining challenges worldwide. Clinical trial successes often have barriers to implementation when disseminated to other areas; whereas strategies that are simple and implementable across all populations of women with HIV have been most successful -such as WHO recommendations for immediate initiation of ART at the time of diagnosis in pregnancy, regardless of CD4 cell count [4] . As WHO efforts move to harmonizing the ARVs used for adult, pediatric treatment and PMTCT, we are further challenged to assure that the ART regimens recommended have adequate efficacy and safety information among pregnant women and infants.
Newborn HIV vaccines or other immunologic adjuvants, such as monoclonal antibodies, could provide additional protection beyond ARVs, particularly for women who are at high risk of transmission such as those with acute HIV infection in pregnancy, those with ARV-resistant virus and those with uncontrolled viral replication close to delivery. However, testing these agents is challenged by demonstrating efficacy in settings with low HIV transmission (e.g. < 1-2%) because very large patient enrollment would be required to demonstrate efficacy.
The largest remaining barrier to eliminating perinatal HIV transmission is overcoming poor adherence to lifelong ART regimens. The metaanalyses by Nachega et al. [48] documented poor adherence of HIV-infected mothers worldwide to taking ART, particularly after the risk of PMTCT has ceased. Several studies have demonstrated that adherence to maternal ART during the postpartum period is worse than antepartum, and decreased adherence has been associated with increases in breastmilk viremia and increased risk of postpartum transmission [49] [50] [51] . The later postpartum period (>12 months) is often a time of transfer of women from antenatal ART services to general ART clinics, with increased risk of loss to care for up to 25% of women following transfer [52, 53] . After initial viral suppression following starting ART during pregnancy, a number of studies have shown decreased rates of viral suppression at 12 and 24 months postpartum, putting the breastfeeding infant at risk of postnatal infection as well as risk of acquisition of resistant virus [54] [55] [56] . Among women on lifelong ART, one recent study shows that a significant minority of women taking ART preconception enter antenatal care with detectable viremia [57] . Another major challenge is how best to decrease new HIV infections among adolescent females who are continuing to fuel the global HIV epidemic.
FUTURE DIRECTIONS
The findings presented above highlight the substantial progress that has been made in PMTCT over the past two decades but also the challenges to achieve an HIV-free generation. Given the safety concerns with the current ART regimens used for PMTCT noted in a number of studies [58, 59] including PROMISE [29 && ] with increased risk of adverse pregnancy outcomes as well as the association of maternal ART use during pregnancy and breastfeeding with decreased maternal BMD [33 & ], it will be important to test the safety of promising new antiretrovirals such as integrase inhibitors among pregnant and breastfeeding women. Another promising area is adding in immune strategies such as monoclonal antibodies and HIV vaccines as part of perinatal interventions.
Other key areas for future research are to test primary prevention strategies with long-acting ARVs such as Cabotegravir for preexposure prophylaxis among high-risk sexually active adolescents and to test novel strategies to improve maternal adherence to taking lifetime antiretrovirals. The issue of how best to support mothers to adhere to lifetime ART is complex and multifaceted [60] . Innovative strategies reported that look promising are use of peers as well as community interventions [61, 62] . Further implementation science research efforts will need to focus on upscaling successful maternal adherence interventions.
CONCLUSION
The recent trends in PMTCT are encouraging and clinical trial data suggest that transmission rates of less than 1% can be achieved with maternal ART. However, in global programmatic settings, the PMTCT cascade continues to reveal gaps at all points. In addition, current ART regimens for PMTCT are associated with increased rates of adverse pregnancy outcomes; and with rapidly emerging resistance among PMTCT-ART exposed mothers and HIVinfected infants. These findings underscore the importance of studying the safety/pharmacokinetic profile of new ART regimens among perinatal populations as they become available in order to further optimize efficacy while minimizing toxicity of ART regimens used for PMTCT.
